Most current statins, like Lipitor, block the liver’s production of bad cholesterol. Praluent uses a different method in which antibodies target a protein called PCSK9 that generally maintains high levels of cholesterol in the liver (Goldschmidt). Patients currently have to take statin pills orally once a day. Patients who use Praluent will be required to take 75 to 150 milligrams of injections every other week (Clarke). While injections may not be the most ideal form of dosage, patients need to take it less frequently. It’s not that the existing methods aren’t as effective as Praluent; the current cholesterol-lowering methods just aim at a different cause of the problem. Since Praluent is a completely new drug in the market, doctors will not be expected to use this drug as their primary treatment for patients right away. However, for existing patients who do not see results from their current medication, Praluent is an alternative option that only has one competitor of its own class. According to Toni Clarke’s article, another PCSK9-inhibiting drug called Repatha is also waiting for approval by the FDA. …show more content…
The most significant difference between the two drugs is the number of dosage. As stated in the previous paragraph, Praluent requires patients to take 75 to 150 milligrams of injections every other week. On the other hand, Repatha requires injections to be given at around 140 milligrams every other week. Since Praluent and Repatha aims at the problem in similar and equally effective ways, future marketing strategies will be affected by these dosages. One major threat of Praluent’s competitor is that since Repatha is more potent, doctors and healthcare providers will be more likely to assign Repatha to a patient because of its convenience. This is a major problem because doctors are the primary target of the drug. However, Praluent is ideal for most consumers and other entities involved with healthcare because lower dosages of the drug allow pharmaceutical companies to lower the price and make it more affordable for its patients. In addition, insurance companies will be more likely to approve this drug as compared to Repatha due to its low price. Spiking …show more content…
Visually, this requires a clean-cut and solid design that would allow patients to clearly notice the product without any distractions. Any advertisement released out into the market must be informational but easy to understand for the average person. Adverse effects must also be stated clearly so patients will understand the pros and cons of using Praluent as compared to its predecessors. Since Praluent is a completely new drug of its own kind, consumers needs to quickly gain trust in the product in order for it to succeed in the market. Since the mere idea of the drug peaks interest in all stakeholders of healthcare, creating a brand for the drug itself will not be a huge issue. Over time, Praluent will provide a sense of hope and opportunity for all patients with high cholesterol and healthcare providers in the pharmaceutical